Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salbutamol metered-dose inhalation - AstraZeneca

Next Previous
Drug Profile

Salbutamol metered-dose inhalation - AstraZeneca

Alternative Names: Albuterol sulfate metered dose inhalation- Pearl Therapeutics; AS MDI; PT 007

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Phenols; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma

Most Recent Events

  • 06 Nov 2025 Efficacy and adverse event data from the phase III ALTA trial in Asthma presented at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2025)
  • 04 Jun 2025 AstraZeneca completes a phase-III MITCHELL clinical trial in Asthma in USA (Inhalation) (NCT06644924)
  • 10 Feb 2025 AstraZeneca initiates a phase-III MITCHELL clinical trial in Asthma in USA (Inhalation) (NCT06644924)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top